All In Biotech

Drug Trial Radar · NCT02545049

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of Care.

Last checked: Nov 19, 2026Latest source record: Apr 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 7,352 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,352

Actual

Start

Sep 17, 2015

Primary completion

Feb 2, 2021

Study completion Feb 2, 2021

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Sep 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.

Conditions

  • Diabetic Kidney Disease

Interventions

  • Finerenone (BAY94-8862)Drug

    10 mg or 20 mg Finerenone tablet to be given orally, once daily.

  • PlaceboDrug

    Matching placebo to be taken orally, once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.Time frame: From randomization up until the first occurrence of the CV composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.

Locations

975 sites in 48 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Fort Payne, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Mesa, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Prescott, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Bakersfield, California

  • Site not named

    Chula Vista, California

  • Site not named

    Dublin, California

  • Site not named

    El Centro, California

  • Site not named

    Fresno, California

  • Site not named

    Fresno, California

  • Site not named

    La Mesa, California

  • Site not named

    Loma Linda, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Northridge, California

  • Site not named

    Port Hueneme, California

  • Site not named

    Poway, California

  • Site not named

    Rancho Cucamonga, California

  • Site not named

    Rialto, California

  • Site not named

    Roseville, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Rosa, California

  • Site not named

    Torrance, California

  • Site not named

    Vista, California

  • Site not named

    New Haven, Connecticut

  • Site not named

    Waterbury, Connecticut

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Jacksonville, Florida

Showing 40 of 975 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.